Previous studies have suggested that the protective effect of LPL agonists on AF may be linked to chronic inflammation and myocardial fibrosis, while FGF5 may increase the risk of AF through myocardial fibrosis and structural remodeling of the atrium. The gene discussed is FGF5; the disease is Myocardial fibrosis.